Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 59,640	$ 55,570
Short-term investments	329,462	253,374
Accounts receivable, net of allowance of nil at December 31, 2016 and 2015	15,678	19,947
Inventory	11,109	11,346
Other current assets	10,363	9,814
Total current assets	426,252	350,051
Property, plant and equipment, net	65,601	71,336
Goodwill	76,501	76,501
Other assets	517	754
Total assets	568,871	498,642
Current liabilities:
Accounts payable	2,816	2,363
Accrued compensation	18,280	5,998
Accrued clinical trial expenses	7,958	8,220
Other accrued expenses	4,711	4,156
Interest payable	4,198	4,198
Capital lease obligations, current portion	2,908	4,756
Liability related to refundable upfront payment	12,500	0
Deferred revenue, current portion	14,352	21,428
Other current liabilities	4,499	10,127
Total current liabilities	72,222	61,246
Senior secured notes, net	243,464	241,699
Capital lease obligations, less current portion	2,223	1,073
Liability related to the sale of future royalties, net	105,950	116,029
Deferred revenue, less current portion	51,887	62,426
Other long-term liabilities	5,000	9,740
Total liabilities	480,746	492,213
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at December 31, 2016 or 2015	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 153,212 shares and 135,289 shares issued and outstanding at December 31, 2016 and 2015, respectively	15	13
Capital in excess of par value	2,111,483	1,876,072
Accumulated other comprehensive loss	(2,363)	(2,170)
Accumulated deficit	(2,021,010)	(1,867,486)
Total stockholders’ equity	88,125	6,429
Total liabilities and stockholders’ equity	$ 568,871	$ 498,642